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We recently reported that epidermal immunization using the PowderJet particle delivery device with plasmid vector
pcDNA1/EDIM6 encoding rotavirus VP6 of murine strain EDIM induced high levels of serum rotavirus IgG but failed to
protect mice against EDIM infection (Choi, A. H., Knowlton, D. R., McNeal, M. M., and Ward, R. L. (1997) Virology 232,
129–138.). This was extended to determine whether pcDNA1/EDIM4 or pcDNA1/EDIM7, which encode either rotavirus VP4
or VP7, the rotavirus neutralization proteins, could also induce rotavirus-specific antibody responses and if these responses
resulted in protection. Titers of rotavirus serum IgG increased with the first dose in mice immunized with pcDNA1/EDIM7,
but little or no serum rotavirus IgG was detected in mice immunized with pcDNA1/EDIM4. In vitro assays with these plasmids
in rabbit reticulocyte lysates showed that VP4 was expressed but the amount was considerably lower than VP6 or VP7. To
improve expression of VP4 and induction of rotavirus-specific humoral responses, the coding region of VP4 was cloned into
the high-expression plasmid WRG7054 as a fusion protein containing the 22-amino-acid secretory signal peptide of tissue
plasminogen activator (tPA) at its N terminus. In vitro expression of tPA ::VP4 was significantly higher than unmodified VP4,
and mice inoculated with WRG7054/EDIM4 generated high titers of rotavirus IgG. The coding sequence of VP7 without the
first 162 nucleotides was also cloned into WRG7054, but no difference was observed between titers of serum rotavirus IgG
in mice immunized with this plasmid (WRG7054/EDIM7D1–162) and pcDNA1/EDIM7. The rotavirus-specific IgG titers in all
immune sera were predominantly IgG1 indicating induction of Th 2-type responses. None of the mice immunized with any
of the VP4 or VP7 plasmids developed serum or fecal rotavirus IgA or neutralizing antibody to EDIM. When immunized mice
were challenged with EDIM virus, there was no significant reduction in viral shedding relative to unimmunized controls.
Therefore epidermal immunization with VP4 or VP7 alone elicited rotavirus IgG responses but did not protect against
homologous rotavirus challenge. © 1998 Academic Press
INTRODUCTION
Rotaviruses are the most important etiological agents
of severe infantile gastroenteritis in young children ,5
years old (Kapikian et al., 1996). Rotavirus infects the
enterocytes of the small intestines and results in severe
dehydrating diarrhea, which can lead to death (Green-
berg et al., 1994). Mortality due to rotavirus disease is
estimated to be nearly 1,000,000 worldwide each year
(Glass et al., 1996), and vaccination appears to be the
only feasible method of eliminating this annual scourge.
Small animal models have been developed to evaluate
rotavirus vaccine strategies (Ward et al., 1990; Conner et
al., 1996). Using the adult mouse model to study active
immunity, protection was not associated with serotype-
specific neutralizing antibody (McNeal et al., 1992; Ward
et al., 1992) Instead, it was found to correlate with titers
of serum and stool rotavirus IgA (Feng et al., 1994; Mc-
Neal et al., 1994). These titers remained elevated for at
least 14 months after oral immunization with live murine
rotavirus (McNeal and Ward, 1995). The importance of
rotavirus antibody in the maintenance of active immunity
against rotavirus infection has been confirmed using
B-cell-deficient mice (Franco and Greenberg, 1995; Mc-
Neal et al., 1995). Although CD81 cells may also help
mediate short term protection in mice (Franco et al.,
1997), these cells were found to be crucial for resolution
of rotavirus infection in B-cell-deficient JHD mice, which
do not produce antibodies (Franco and Greenberg, 1995;
McNeal et al., 1995). Recent evidence with immunocom-
petent BALB/c mice, however, indicated that resolution of
rotavirus shedding was due to the combined effects of
CD81 cells and CD41 cell-dependent antibodies (Mc-
Neal et al., 1997). Thus both cell-mediated and humoral
responses are involved in rotavirus immunity in mice.
The rotavirus capsid is arranged into three concentric
layers (Prasad and Chiu, 1994; Yeager et al., 1994). The
outermost layer is composed of 60 VP4 dimers and 720
molecules of VP7 (Prasad et al., 1988, 1990). VP4 and VP7
determine the serotypes of rotavirus, defined as P and G
types, respectively, and independently induce neutraliz-
ing antibodies (NA). Antibodies to VP4 and VP7 can
passively protect mice against rotavirus challenge (Offit
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et al., 1986; Matsui et al., 1989; Mackow et al., 1990;
Andrew et al., 1992; Both et al., 1993). In addition, VP7
also contains CTL epitopes, which may be important to
protective immunity (Offit et al., 1991, 1994). The recent
development of tetravalent rotavirus vaccines has been
based primarily on the presumptive importance of VP7 in
protection (Clark et al., 1996; Kapikian et al., 1996). Vac-
cine strategies based on VP4 are also being tested
(Clark et al., 1996).
The middle capsid layer of rotavirus is composed of
780 molecules of VP6 (Prasad et al., 1996), which carries
antigenic determinants that define both group and sub-
group specificities (Greenberg et al., 1983; Lambert et al.,
1984; Gorziglia et al., 1988; Gerna et al., 1989; Lopez et
al., 1994). A recent study using a hybridoma backpack
model has demonstrated that nonneutralizing anti-VP6
antibody secreted by injected hybridoma cells provided
protection in the mouse model (Burns et al., 1996). To
determine whether the VP6 protein itself could induce
immunity using DNA-based immunization, we recently
injected mice epidermally using the PowderJet particle
delivery device (commonly known as the gene gun) with
plasmid pcDNA1/EDIM6 expressing VP6 of rotavirus
strain EDIM. It was found that immunized mice devel-
oped high titers of serum rotavirus IgG but were not
protected against rotavirus infection (Choi et al., 1997). In
contrast, results by Herrmann and co-workers (Herr-
mann et al., 1996a,b; Chen et al., 1997) suggested that
protective immunity could be induced in mice following
gene-gun immunization with a plasmid expressing VP6.
In addition, these investigators reported that mice follow-
ing gene-gun immunization with plasmids expressing
VP4 or VP7 were also protected from challenge with
murine rotavirus. In this study, we immunized mice using
the gene gun with a plasmid expressing unmodified VP4
or VP7 of rotavirus strain EDIM, and a plasmid express-
ing chimeric tPA ::VP4 or tPA ::TrVP7, which contain the
secretory signal peptide from tissue plasminogen acti-
vator (tPA). This was done to determine whether immune
responses against these neutralization proteins and pro-
tection from viral shedding could be elicited in mice.
RESULTS
Immunization of mice with pcDNA recombinants
To determine whether rotavirus-specific antibodies
could be generated against VP4 or VP7, groups of six
BALB/c mice were immunized epidermally in the abdo-
men (2 sites/dose) using the gene gun with 2 mg doses
of pcDNA/4 (3 doses) or pcDNA/7 (4 doses) at 4-week
intervals. A third group of six mice was inoculated with
pcDNA/6 (2 mg/dose, 3 doses) which we have already
shown to induce high titers of serum rotavirus IgG (Choi
et al., 1997). Titers of serum rotavirus IgG in blood spec-
imens that were collected after each immunization were
measured by ELISA. Mice injected with pcDNA/6 gener-
ated serum rotavirus IgG with kinetics of induction and
titers that were similar to those reported earlier (Table 1).
Mice immunized with pcDNA/4 did not generate any
measurable serum rotavirus IgG. In contrast, pcDNA/7-
immunized mice developed serum rotavirus IgG begin-
ning after the second immunization, and the titers rose
steadily after the third and fourth inoculations (Table 1).
In vitro expression of pcDNA recombinants
The lack of immune responses in mice immunized
with pcDNA/4 might have resulted from poor expression
of VP4. An in vitro transcription and translation assay
(TNT) was used to determine whether the VP4 gene
contained in pcDNA/4 could be expressed. Expression of
VP4 was compared with that of VP6 and VP7 by SDS–
PAGE and autoradiographic analyses (Fig. 1A). Proteins
with apparent molecular masses of 84, 42, and 37 kDa,
which are the expected sizes of VP4, VP6, and VP7,
respectively, were observed. However, expression of VP4
by pcDNA/4 was considerably lower than that of VP6 or
VP7.
TABLE 1
GMTs of Serum Antirotavirus IgG in BALB/c Mice Immunized with Plasmids Expressing Rotavirus Proteins
Plasmid
No. of
mice
Serum rotavirus IgG (U/ml)a
Preimmune Postdose 1 Postdose 2 Postdose 3 Postdose 4
pcDNA/4 6 ,100b ,100 ,100 ,100 NAc
pcDNA/6 6 ,100 450 6 1,180
(,100–5,886)d
136,295 6 93,871
(16,828–642,812)
259,695 6 112,945
(75,305–829,357)
NA
pcDNA/7 6 ,100 ,100 192 6 246
(,100–1,619)
8,766 6 15,725
(885–101,780)
58,230 6 29,088
(16,130–148,060)
a IgG titers are expressed as GMT (geometric mean titer) 6 SE (standard error).
b Titers of ,100 U/ml indicate that no antirotavirus IgG was detected. A value of 50 U/ml was used for calculations of GMTs.
c NA, Not applicable.
d Ranges are shown in parenthesis.
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In vitro expression of WRG recombinants
Due to the low levels of expression by pcDNA/4, the
sequence encoding VP4 was subcloned into the plasmid
WRG7054 which could potentially express VP4 at a
higher level because it contains the CMV intron A se-
quence, which has been shown to increase expression
of transgenes (Chapman et al., 1991). WRG7054 also
contains a sequence encoding 22 residues of the 23-
amino-acid signal peptide of the secretory protein tPA
(Jarvis et al., 1993). When the tPA signal is expressed at
the N terminus, it should transport the fusion proteins
into the endoplasmic reticulum (ER) and enable their
secretion. VP4 and chimeric tPA ::VP4 were expressed in
vitro and then analyzed by SDS–PAGE and autoradiog-
raphy. The amount of expressed tPA ::VP4 was consider-
ably greater than VP4 (Figs. 1A and 1B). tPA ::VP4 con-
tains the 22-amino-acid tPA secretory signal peptide and
two amino acids from the multiple cloning site at its N
terminus. Consequently, it migrated slightly slower than
VP4. To determine whether VP4 could similarly be ex-
pressed in greater amounts from WRG7054, the gene
sequence encoding TrVP7, a truncated form of VP7, was
subcloned into this plasmid. The truncation resulted in
the deletion of the N-terminal 54 amino acids containing
the H1 and H2 ER-transport domains and residues that
participate in the retention of VP7 in the ER (Kabcenell
and Atkinson, 1985). SDS–PAGE and autoradiographic
analyses of VP7 and tPA ::TrVP7 expressed in vitro re-
vealed no significant difference between the expression
levels of these two forms of VP7 (Fig. 1A). tPA ::TrVP7
contains 30 amino-acid residues less than VP7 and con-
sequently it migrated slightly ahead of VP7.
Translocation of recombinant proteins into
microsomes
The function of the tPA signal of fusion proteins
tPA ::VP4 and tPA ::TrVP7 was examined by in vitro ex-
pression of these proteins in the presence of micro-
somes. Both unmodified VP7, which contains the ER-
translocation domains at its N terminus (Kabcenell and
Atkinson, 1985), and tPA ::TrVP7 was expected to be
transported into the microsomes where glycosylation of
VP7 would take place. Unmodified VP4, which does not
have a signal peptide, was not expected to be translo-
cated into microsomes, whereas chimeric tPA ::VP4 was
anticipated to be translocated. Although potential
N-linked glycosylation sites (Asn-X-Ser/Thr) are present
in VP4 (Asn-32, -56, -111, -116, -132, -169, -196, -288, and
-669), tPA ::VP4 was not expected to be glycosylated
because VP4 is not glycosylated despite the transient
residency of VP4-containing subviral particles in the ER
(Mason et al., 1980; Arias et al., 1982; McCrae and Mc-
Corquodale, 1982; Au et al., 1989; Crawford et al., 1994).
SDS–PAGE and autoradiographic analyses indicated the
presence of glycosylated tPA ::TrVP7 and VP7, which ap-
peared as slow migrating forms of the proteins (Fig. 2A).
Unexpectedly, tpA ::VP4 was also glycosylated, thus pro-
viding direct evidence that tPA ::VP4 was translocated
into microsomes. To confirm that the slow migrating
forms of tPA ::VP4, tPA ::TrVP7, and VP7 were indeed gly-
cosylated proteins, recombinant endo-H, which cleaves
the chitobiose core of high mannose and certain hybrid
oligosaccharides from N-linked glycoproteins (Robbins
et al., 1984), was added after protein expression in the
presence of microsomes. Following digestion, only the
fast migrating forms of these proteins were observed in
autoradiograms (Fig. 2B). This observation provided fur-
ther evidence that not only tPA ::TrVP7 and VP7 were
glycosylated but that tPA ::VP4 was also glycosylated in
microsomes.
Immunization of mice with WRG7054 constructs
A group of eight mice was immunized using the gene
gun with WRG/4 (2 mg/dose, 4 doses) to determine
whether expression of tPA ::VP4 could generate serum
rotavirus antibodies. Blood specimens were collected at
3–4 weeks following each immunization, and serum ro-
tavirus IgG was measured using ELISA (Table 2). Titers
of rotavirus antibodies were generated in all WRG/4-
immunized mice following the second inoculation, and
the titers rose following the third but not the fourth
immunization. The group of mice immunized with
FIG. 1. In vitro expression of rotavirus proteins. Recombinant VP4,
VP6, and VP7 were expressed from pcDNA/4, pcDNA/6, and pcDNA/7,
respectively, and recombinant tPA ::VP4 and tPA ::TrVP7 from WRG/4
and WRG/D7, respectively. Expression was carried out in rabbit reticu-
locyte lysates using T7 RNA polymerase and labeled with [35S]methi-
onine as described under Materials and Methods. Following protein
synthesis, samples were heated in SDS-PAGE sample buffer at (95°C,
5 min) and subjected to electrophoresis and autoradiography. (A) Au-
toradiogram developed after 6 h exposure. (B) Since VP4 was not
readily detected after 6 h exposure, an autoradiogram was obtained
after 24 h exposure to visualize this protein. Recombinant rotavirus
proteins with expected molecular weights are indicated by arrows.
Numbers to the left are molecular weights of markers in kDa.
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pcDNA/4 generated little or no rotavirus IgG as observed
previously. Groups of mice were also immunized with
either WRG/D7 or pcDNA/7 to determine whether re-
placement of the VP7 ER-translocation signal domains
with the tPA signal peptide would affect induction of
serum rotavirus IgG. Specific IgG titers were generated
after the second immunization in all eight WRG/D7-im-
munized mice. In contrast, zero of five pcDNA1/7-immu-
nized mice had detectable serum rotavirus IgG after two
immunizations. After the fourth immunization, however,
the two groups of mice developed nearly equal (P 5
0.75) titers of rotavirus IgG. Control groups developed no
detectable rotavirus IgG. Titers of serum and fecal rota-
virus IgA were also measured by ELISA, but none was
detected in mice immunized with any of the plasmids. In
addition, no detectable serum NA to EDIM was devel-
oped in immunized animals (results not shown).
Western blot analyses
Immune sera were used in Western blot analyses to
determine whether antibodies generated against the re-
combinant rotavirus proteins could recognize cognate
rotavirus proteins that were separated by SDS–PAGE
and transferred to nitrocellulose strips. VP6 and VP7
were readily recognized by pcDNA/6-, pcDNA/7-, and
WRG/D7-immune sera, respectively (Fig. 3). Furthermore,
VP4 could be detected by WRG/4-immune sera but not
pcDNA/4-immune sera. This inability of pcDNA/4 to stim-
ulate antibodies that recognize even denatured VP4 pro-
vides further evidence that VP4 is poorly expressed in
mice immunized with this plasmid.
Because VP4 and VP7 can both elicit NA responses
following immunization with triple-layered rotavirus par-
ticles, it is unclear why the IgG generated against these
FIG. 2. Translocation of recombinant VP7, tPA ::VP4, and tPA ::TrVP7
into canine microsomal membranes. Recombinant VP4, VP6, and VP7
were expressed from pcDNA/4, pcDNA/6, and pcDNA/7, and recombi-
nant tPA ::VP4 and tPA ::TrVP7 were expressed from WRG/4 and WRG/
D7. Expression was carried out in rabbit reticulocyte lysates containing
T7 RNA polymerase, [35S]methionine and microsomes. Following pro-
tein synthesis, samples were divided into equal portions, one of which
received only digestion buffer (A) and the other received Endo-H in
digestion buffer (B). SDS–PAGE sample buffer was added to the sam-
ples (37°C for 30 min) and the samples were analysed by SDS–PAGE
and autoradiography. The small arrow heads () indicate multimeric
forms of VP6 that are stable at 37°C, the large black arrows (g) indicate
VP4, VP6, or VP7, and the open arrows (G) indicate glycosylated VP7,
tPA ::VP4, and tPA ::TrVP7. Numbers to the left are molecular weights of
markers in kDa.
TABLE 2
GMTs of Serum Antirotavirus IgG in Mice Immunized with Plasmids Expressing Rotavirus Proteins
Plasmid
No. of
mice
Antirotavirus IgG (U/ml)a
Preimmune Postdose 1 Postdose 2 Postdose 3 Postdose 4
None 6 ,100b ,100 ,100 ,100 ,100
WRG5074 6 ,100 ,100 ,100 ,100 ,100
WRG/4 8 ,100 80 6 46
(,100–414)c
6,024 6 2,899
(1,284–22,934)
53,010 6 7,681
(18,370–95,788)
51,525 6 8,554
(14,463–90,803)
pcDNA/4 8 ,100 ,100 ,100 57 6 10
(,100–139)
59 6 17
(,100–198)
pcDNA/6 6 ,100 1,073 6 313
(406–2,159)
35,883 6 9,052
(17,078–75,430)
95,082 6 7,911
(69,539–116,398)
120,816 6 13,796
(67,058–167,458)
WRG/D7 8 ,100 121 6 39
(,100–379)
1,049 6 143
(771–1,902)
5,469 6 1,122d,e
(1,706–8,231)
1,446 6 518f
(701–5,032)
pcDNA/7 5 ,100 68 6 32
(,100–230)
,100 665 6 1,780
(228–10,302)
1,212 6 1,010
(310–6,490)
a Antirotavirus IgG titers are expressed as GMT 6 SE.
b Titers of ,100 U/ml indicate that no antirotavirus IgG was detected. A value of 50 U/ml was used for calculations.
c Ranges of antirotavirus antibody are shown in parenthesis.
d Not significantly (P 5 0.16, Student’s t-test, unpaired, 2-tailed) higher than postdose-3 titers of pcDNA/7-immunized mice.
e Significantly (P 5 0.01) higher than postdose-4 titers.
f Not significantly (P 5 0.75) higher than postdose-4 titers of pcDNA/7-immunized mice.
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proteins following DNA immunization did not have de-
tectable neutralizing activity. We have consistently ob-
served that mice orally immunized with live EDIM de-
velop high titers of serum IgG but little or no NA to EDIM.
Using sera from a group of mice that developed low NA
titers to EDIM following infection (GMT 5 24), VP4 was
readily recognized by Western blot analyses but little
antibody appeared to be generated against VP7 in these
mice (Fig. 3). Furthermore, a group of EDIM-infected
mice that did not produce detectable NA to EDIM still
produced antibody that readily recognized EDIM VP4
(Fig. 3). Therefore, antibody produced against VP4 in this
latter group of mice, although not neutralizing, did rec-
ognize denatured VP4. From this it is not unexpected that
antibodies produced following DNA immunization with
plasmids containing VP4 and VP7 genes recognized
their denatured cognate proteins but did not have neu-
tralizing activity.
DNA immunization generated Th 2-type responses
The relative titers of specific IgG1 and IgG2a is an
indicator of the types of T help (Th) responses being
induced. The relative titers of these IgG subclasses gen-
erated in mice have been found to be dependent on the
route of DNA vaccination (Robinson, 1997). Gene-gun
immunization generates predominantly IgG1 titers char-
acteristic of a Th 2-type response, whereas greater titers
of IgG2a are predominant in mice vaccinated by intra-
muscular immunization indicating a Th 1-type response
(Robinson, 1997). Titers of rotavirus IgG1 and IgG2a in
immune sera were quantified. The IgG1/IgG2a ratios
were 35:1, 65:1, and 29:1 for tPA ::VP4, VP6, and
tPA ::TrVP7, respectively. The high IgG1/IgG2a ratio indi-
cated that a predominantly Th 2-type response was gen-
erated. Following EDIM challenge, DNA vaccinated ani-
mals continued to maintain high rotavirus IgG1/IgG2a
ratios (results not shown).
Lack of protection in immunized mice against EDIM
Immunized mice were orally challenged with 100 ID50
of live EDIM virus at 14 days after the last immunization
to determine whether they were protected from infection.
Shedding of rotavirus began on Day 1 or Day 2 after
challenge in all groups of immunized mice and continued
for the 7-day period studied (Fig. 4). The amounts of
shedding by immunized mice were not significantly dif-
ferent from unimmunized controls. Therefore immunized
mice were not protected from EDIM challenge.
DISCUSSION
In this study, plasmids pcDNA/4, pcDNA/7, WRG/4, and
WRG/D7 were constructed for DNA-based immunization
in a mouse model developed for studies of active immu-
nity (Ward et al., 1990). Mice were immunized with these
DNA vaccines using the gene gun to determine whether
rotavirus antibody responses and protective immunity
could be induced against challenge by murine rotavirus
strain EDIM. Plasmids pcDNA/4 and pcDNA/7 express
unmodified VP4 and VP7. WRG/4 expresses chimeric
protein tPA ::VP4, which contains, at its amino terminus, a
22-amino-acid secretory signal peptide of tissue plas-
minogen activator (tPA) followed by two additional amino
acids (Arg and Pro) of the multiple cloning site. WRG/D7
expresses tPA ::TrVP7 in which the tPA peptide and the
amino acids Arg and Pro have replaced the N-terminal
54 amino acids of VP7. These amino acids were deleted
FIG. 4. Rotavirus antigen shedding profiles of immunized mice chal-
lenged with EDIM. Groups of mice were immunized (4 doses) with
plasmids expressing tPA ::VP4, tPA ::TrVP7, VP4, VP6, or VP7. Control
mice were either inoculated with WRG7054 or not inoculated. Immu-
nized animals were challenged at 14 days following the last inoculation
with an oral dose of 100 ID50 of EDIM. Stool specimens were collected
on the day of challenge and for 7 days. Quantities of rotavirus in the
stool samples were determined by ELISA as described under Materials
and Methods. Mean rotavirus antigen shedding for each group is
expressed as mean A490 and error bars denote standard errors.
FIG. 3. Western blot analyses of immune sera. Triple-layered EDIM
rotavirus particles were subjected to SDS–PAGE, then blotted onto a
nitrocellulose sheet which was cut into strips. The strips were incu-
bated with the specified immune sera, followed by goat anti-mouse IgG
conjugated to alkaline phosphatase, and then BCIP and NBT. No NA,
no neutralizing antibodies detected.
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because they participate in targeting and retention of
VP7 in the ER (Stirzaker et al., 1987; Stirzaker and Both,
1989; Stirzaker, 1990; Maass and Atkinson, 1994) and,
therefore may not be compatible with the secretory func-
tion of tPA. In Western blot analyses, WRG/4- and WRG/
D7-immune sera recognized cognate virion proteins,
which were separated by SDS–PAGE and transferred
onto nitrocellulose sheets, indicating that chimeric
tPA ::VP4 and tPA ::TrVP7 generated VP4- and VP7-spe-
cific antibodies. Thus the addition of the tPA peptide to
the N terminus of VP4 or VP7 did not affect their ability to
induce VP4- and VP7-specific antibodies. A similar ob-
servation has been made with a recombinant VP6 called
VP6sc. VP6sc was engineered to be transported to the
ER and expressed on the cell surface (Greenberg et al.,
1983; Reddy et al., 1992). Unlike unmodified VP6, VP6sc
has been found to be glycosylated, and glycosylation has
not been found to affect the ability of VP6sc to bind
antibodies or form structures typical of VP6.
Mice inoculated with WRG/4 generated high titers of
serum rotavirus-specific IgG. In contrast, no anti-VP4
antibodies were detected by Western blot analyses or by
ELISA (using native VP4) or by Western blot analysis
(using denatured VP4) in mice inoculated with pcDNA/4.
Differences in immune responses between plasmids
could not have been due to differences in the VP4 genes
of the two plasmids because the VP4 gene in WRG/4 had
been subcloned from pcDNA/4. To further investigate the
possible causes for the absence of anti-VP4 antibodies
in pcDNA/4-immune sera, vaccine DNA was recovered
from unused samples of plastic bullets, each of which
was coated with a starting amount of 2 mg DNA. All
bullets tested had been found to contain vaccine DNA
with a recovery efficiency of 65 6 29% (mean 6 standard
deviation). Furthermore, the quantity of pcDNA/4 mea-
surable was consistently greater than that of WRG/4.
Therefore, the failure to detect anti-VP4 antibodies in
immune sera of pcDNA/4-immunized mice was not
caused by the absence of deposited DNA on the plastic
tubes. In vitro expression was performed to ascertain the
level of VP4 expression. SDS–PAGE and autoradio-
graphic analyses revealed that VP4 was expressed but
the amount was considerably lower than that of tPA ::VP4.
The high expression level of tPA ::VP4 may be due to the
presence of CMV IE enhancer/promoter/intron A se-
quence, which has been shown to generate high levels
of transgene expression (Chapman et al., 1991; Mont-
gomery et al., 1993). However, it is also possible that the
increased immune responses to tPA ::VP4 might result
from secretion of tPA ::VP4 from transfected cells.
Contrary to mice inoculated with pcDNA/4, pcDNA/7-
immunized mice produced moderate amounts of rotavi-
rus IgG. Furthermore, final titers of serum rotavirus IgG
that were generated in mice after four immunizations
with pcDNA/7 were not significantly different from WRG/
D7. It should be noted that titers of serum rotavirus IgG in
the pcDNA/7-immunized group in the second experiment
were significantly lower than the first experiment (Table
1 and Table 2, P 5 0.01). Because the bullets used for
DNA immunization contained comparable amounts of
plasmids in the two experiments, this cannot be the
explanation. The difference in immune responses was
probably due to differences in the inherent immunologi-
cal properties between the two shipments of BALB/c
mice used for these experiments. Differences in immu-
nological responses and virus shedding are commonly
observed between different shipments of this inbred
mouse strain (unpublished results). Other explanations
such as subtle differences in plasmid preparations are
also possible. When SDS–PAGE and autoradiographic
analyses were performed with the sera obtained from
WRG/D7- and pcDNA/7-immunized animals, no differ-
ence in antibody concentrations was observed by ELISA.
Furthermore, virion VP7 was stained equally well by
pcDNA/7- or WRG/D7-immune sera by Western blot anal-
yses. The observation that unmodified VP7 and
tPA ::TrVP7 induced similar immune responses is in
agreement with the results obtained using recombinant
vaccinia viruses to express unmodified VP7 and chimeric
VP7 (Andrew et al., 1990, 1992; Both et al., 1992). In those
studies, titers of rotavirus antibodies generated by ex-
pressed VP7 and a secretory form of VP7 containing the
influenza hemagglutinin were found to be similar.
All immunized groups with the exception of the
pcDNA/4-inoculated group developed moderate to high
titers of serum rotavirus IgG. Despite this, immunized
mice were not protected from infection by EDIM. Follow-
ing primary infection with EDIM rotavirus, mice have
been shown to generate and maintain high titers of
serum rotavirus IgG and IgA, as well as stool rotavirus
IgA, and were protected for at least 14 months (McNeal
and Ward, 1995). It was also found that titers of rotavirus
IgA, rather than serum rotavirus IgG, were correlated
with protection (Feng et al., 1994; McNeal et al., 1994).
The results obtained here with vaccine DNA-immunized
mice support the conclusion that serum rotavirus IgG
does not correlate with protection. No measurable serum
or stool rotavirus IgA was generated, the absence of
which might have resulted in the failure to protect immu-
nized mice. However, the failure to induce protection
might also be due to the absence of protective compo-
nents other than IgA because it has been observed that
mice immunized parenterally with either inactivated or
live EDIM were completely protected when little if any
rotavirus IgA was induced (unpublished results).
We previously reported that mice immunized by gene-
gun inoculation developed extremely high titers of anti-
rotavirus IgG following EDIM challenge (Choi et al.,1997).
In the present study, postchallenge rotavirus IgG titers in
pcDNA/7-, WRG/4-, and WRG/D7-immunized mice were
also significantly higher (P , 0.01) than the correspond-
ing postvaccination IgG titers of unimmunized mice (re-
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sults not shown). Even for the pcDNA/4-immunized
group, the postchallenge titers were significantly higher
(P 5 0.01) than the postchallenge titers of the uninocu-
lated control groups. This observation indicated that,
although no specific IgG was detected, VP4-specific
memory B cells were induced by DNA vaccination with
pcDNA/4. None of the DNA-immunized groups devel-
oped postvaccination rotavirus IgA, and although every
DNA-immunized group developed postchallenge serum
and stool IgA, the IgA titers were not significantly differ-
ent from that of the unimmunized controls. These results
indicated that none of the DNA-vaccinated groups devel-
oped rotavirus-specific IgA memory B cells.
Studies of DNA-based immunization of mice with plas-
mids expressing VP4, VP6, or VP7 of rotavirus strain
EDIM using the gene gun had also been recently per-
formed by Herrmann and coworkers who reported that
immunized mice were partially protected from viral shed-
ding upon challenge with a murine virus (Herrmann et al.,
1996a,b; Chen et al., 1997). In those studies, as well as
our own, gene-gun-immunized mice developed much
higher titers of IgG1 than IgG2a, indicating T helper cell
responses were predominantly Th 2 in both laboratories.
Although Th 2-type responses favor IgA production, no
postvaccination rotavirus IgA was detected in either
study. Herrmann and coworkers reported that the VP4
and VP7 DNA based-vaccines stimulated ‘‘detectable’’ NA
responses. In contrast, we were unable to measure NA
in any of our DNA-immune sera. This difference, how-
ever, does not account for differences in protection be-
tween the two studies because protection was also re-
ported by Herrmann and coworkers in mice immunized
with plasmids containing VP6, which elicits no NA re-
sponses. Furthermore, no correlation with active immu-
nity in mice for either serum or intestinal NA was found
following either oral or parenteral (intraperitoneal) inoc-
ulation with EDIM rotavirus (McNeal et al., 1992; Ward et
al., 1992). The procedures used in our laboratory and that
of Herrmann and coworkers were very similar including
the animal model itself, the plasmids, the protocol, and
the method of inoculation. Therefore we cannot reconcile
the differences found in observed protection at this time.
Because DNA-based vaccination is potentially a power-
ful measure of immunization against rotavirus, further
experimentation should be performed to better evaluate
and augment its usefulness.
MATERIALS AND METHODS
Virus
The origin of the murine EDIM strain of rotavirus used
in this study has already been described (Ward et al.,
1990). It was isolated from the stool of an infected mouse
and adapted to grow in cell culture by passage in MA-
104 cells. After nine passages, a viral lysate was pre-
pared and used to challenge mice in all studies. A triply
plaque purified isolate of this passage was used to infect
MA-104 cells to yield stock virus for RNA purification and
for serum NA determination.
Purification of virus RNA
Rotavirus RNA was purified as previously described
(Choi et al., 1997). Briefly, EDIM-infected MA-104 cells
were incubated with Triton X-100 (1%, 30 min, room
temperature). Insoluble cell debris was removed by cen-
trifugation (800 g, 30 min, 4°C), and the resulting super-
natant was further centrifuged (5500 g, 90 min, 4°C) to
pellet the virions. The crude virus pellet was resus-
pended in TE buffer (10 mM Tris, pH 7.5, 1 mM EDTA).
Viral RNA was isolated using TRIzol (Life Technologies,
Gaithersburg, MD) according to the protocol of the sup-
plier.
RT–PCR
Double-stranded (ds) cDNA was generated by reverse
transcription–polymerase chain reaction (RT–PCR) from
gene segments encoding VP4 or VP7 of rotavirus as
described for the gene encoding VP6 (Choi et al., 1997).
Essentially, 1 mg of purified genomic rotavirus RNA was
denatured (3 min, 94°C) in 10 ml of distilled water con-
taining 10% DMSO and 150 ng of both a forward and
reverse primer. The forward primer was 59-GGCTATA-
AAATG-39 and the reverse primer was 59-GGTCACATC-
CTCTAGACACTGCTC-39 for gene 4. For gene 7, the for-
ward primer was 59-GGCTTTAAAAGAGAGAATTTC-39
and the reverse primer was 59-GGTCACATCATACAGCT-
GTAA-39. The primers used were based on the terminal
sequences of the 59 and 39 noncoding regions (NCR) of
the gene encoding VP4 (GenBank Accession No.
U08429) and the gene encoding VP7 (GenBank Acces-
sion No. U08430) of murine rotavirus strain EW, whose
origin was the same as that of EDIM.
Construction of pGEM-3Z/EDIM4 and
pGEM-3Z/EDIM7
Recombinant plasmids pGEM-3Z/EDIM4 and pGEM-
3Z/EDIM7 containing genes encoding VP4 or VP7 were
constructed by cloning ds cDNA of these genes into the
SmaI site of pGEM-3Z in the same manner as described
for gene 6 (Choi et al., 1997).
Construction of the pcDNA1/EDIM4 and pcDNA1/
EDIM7
For DNA-based immunization, the mammalian expres-
sion plasmids pcDNA1/EDIM4 and pcDNA1/EDIM72
were constructed by subcloning the entire genomic se-
2 For brevity, pcDNA1/EDIM14, pcDNA1/EDIM16, and pcDNA1/
EDIM7 are hereafter referred to as pcDNA/4, pcDNA/6, and pcDNA/7.
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quence containing VP4 or VP7, from pGEM-3Z/EDIM4 or
pGEM-3Z/EDIM7, into pcDNA1 (Invitrogen, Carlsbad,
CA). The VP4 gene was subcloned into the BamHI and
SphI sites and the VP7 gene into BamHI and XbaI sites,
placing the genes under the control of the T7 promoter
and the human CMV immediate-early (IE) promoter and
the SV40 polyadenylation signal/intron sequence. The
nucleotide sequences of VP4 and VP7 in these plasmids
were obtained by sequencing the genes in both direc-
tions using the CircumVent thermal cycle DNA sequenc-
ing kit (New England Biolabs, Beverly, MA) and
[a-35S]dATP, or using the Silver sequencing system (Pro-
mega, Madison, WI) according to the protocols of the
suppliers. The nucleotide sequences encoding VP4 and
VP7 have been submitted to GenBank nuleotide se-
quence database and have been assigned the Acces-
sion Nos. AF039219 and AF039220, respectively.
Construction of WRG7054 expressing VP4 or VP7
To improve expression of VP4 and to increase the
possibility of inducing specific immune responses, the
open reading frame encoding VP4 from pcDNA/4 was
subcloned into WRG7054 (Yanisch-Perron et al., 1985; a
gift from J. Fuller, PowderJet, Middleton, WI) to create
WRG7054/EDIM4 for gene-gun immunization. WRG7054
contains the CMV IE promoter/enhancer/intron A, the
bGH polyadenylation signal, and a 66-nucleotide se-
quence from the tPA secretory signal peptide, which
enables an inframe insert to be expressed as a secretory
fusion protein. Using the forward primer 59-ATGGCT-
TCACTCATTTATAGACAA-39 and the reverse primer 59-
TCACAGTCTACACTGCATAATTAA-39, ds cDNA encoding
VP4, which contains 775 amino acids, was generated
from pcDNA/4 by PCR and cloned into the SmaI site of
WRG7054. Insertion into the SmaI site resulted in the
addition of six nucleotides, encoding for Arg and Pro,
between the tPA signal peptide and VP4. For construc-
tion of WRG7054/EDIM7D1–162,
3 which encodes a trun-
cated form of VP7 beginning with amino-acid-residue 55
to the carboxyl end of the protein (amino-acid-residue
326), ds cDNA was first synthesized using pcDNA/7 as
the template, the forward primer 59-ATTAATCTTCCAAT-
TACTGGTTCAATGGAC-39 (nucleotide 163–192 of the
open reading frame of VP7), and the reverse primer
59-TAACTTCAGTTATACCTACACTCT-39 (nucleotide 958–
981). The cDNA also was inserted into the SmaI site.
In vitro expression of recombinant proteins
The TNT quick coupled transcription/translation sys-
tem (Promega), which contains rabbit reticulocyte ly-
sates, T7 RNA polymerase for transcription, and [35S]me-
thionine for peptide labeling, was used to examine in
vitro protein expression. To characterize expression of
the fusion proteins tPA ::VP4 and tPA ::TrVP7, the coding
frames for these proteins were subcloned from WRG/4
and WRG/D7, which do not possess T7 promoter, into
pcDNA1 creating pcDNA1/tPA-EDIM4 and pcDNA1/tPA-
EDIMD7. For this, PCR products were generated using
these WRG recombinants as templates, a common for-
ward primer designed from the tPA signal sequence
(59-ATGGATGCAATGAAGAGAGGGCTC-39) and the re-
verse primers for genes encoding VP4 or VP7 as de-
scribed above for the construction of WRG7054 recom-
binants. The TNT reaction mixture consisted of 25 ml of
rabbit reticulocyte lysate, T7 polymerase, 20 mM amino
acid mixture minus methionine, 0.8 mCi of [35S]methi-
onine (Amersham, Arlington Heights, IL), 0.8 U of RNasin
ribonuclease inhibitor (Promega), and 0.3 pmoles of
pcDNA1/tPA-EDIM4 or pcDNA1/tPA-EDIMD7. Following
protein synthesis (90 min, 30°C), SDS–PAGE gel loading
buffer (50 mM Tris, pH 6.8; 10% glycerol; 2% SDS; 0.005%
bromphenol blue) was added to the reaction mixtures.
The mixtures were incubated either at 37°C (30 min) or
95°C (5 min) and then subjected to electrophoresis on
10% SDS–polyacrylamide gels. The gels were fixed and
dried. Autoradiography was performed using XAR-5 film
(Eastman Kodak, Rochester, NY).
In vitro expression of recombinant proteins in the
presence of microsomes
To ascertain that expressed VP7 could be glycosy-
lated, TNT reactions were performed in the presence of
canine microsomal membranes (90 min, 30°C). To fur-
ther determine whether glycosylation involved N-linked
high mannose carbohydrates, recombinant endo-H
[endo-b-N-acetylglucosaminidase-H (New England Bio-
labs), 100 U/ml in 50 mM sodium citrate buffer, pH 5.5
containing 0.5% SDS, and 1% b-mercaptoethanol] was
added, following protein synthesis, to the reaction mix-
ture (60 min, 37°C).
Preparation of DNA vaccines
DNA vaccines, i.e., plasmids expressing rotavirus pro-
teins, used for immunization of mice were purified from
Escherichia coli by alkaline lysis and using pZ523 col-
umns (5 Prime To 3 Prime, Boulder, CO). Removal of
lipopolysaccharide, a frequent contaminant of plasmid
DNA preparations, was performed according to the
method of Cotton et al. (1991). Sodium acetate (0.3 M, pH
5.2) and Triton X-114 (30 ml/ml) were added to plasmid
preparations, which were vortexed, incubated on ice (10
min) and then at 30°C (5 min). After centrifugation in a
microcentrifuge (2 min), the aqueous phase was recov-
ered. The aqueous phase was extracted two additional
times as described above, and the plasmids in the aque-
ous phase were precipitated with isopropanol (0.6 vol,
3 For brevity, WRG7054/EDIM4 and WRG7054/EDIM7D1–162 are re-
ferred to as WRG/4 and WRG/D7.
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room temperature). Plasmids were washed twice with
80% ethanol and resuspended in TE buffer.
Mice
Female BALB/c mice (Harlan-Sprague-Dawley, India-
napolis, IN) were used for all experiments. Mice were
housed in groups of four in sterile microisolation cages.
All procedures were conducted in accordance with pro-
tocols reviewed and approved by the Children’s Hospital
Research Foundation Institutional Animal Care and Use
Committee.
DNA-based immunization of mice
DNA vaccines that were used to immunize mice were
prepared by depositing recombinant plasmids onto gold
beads (2.1 mm-diameter) according to the instructions of
PowderJet Vaccine, Inc. (Madison, WI). DNA vaccines
were coated on the inside of plastic tubings, which were
then cut into 0.5-inch ‘‘bullets,’’ each of which was coated
with 2 mg DNA and 0.5 mg of gold particles. To ensure
that DNA was deposited on the tubings, bullet samples
were placed in microcentrifuge tubes containing 0.6 ml
of TE buffer (10 mM Tris–HCl, pH 7.5; 1 mM EDTA). The
DNA-coated gold beads were dislodged from the tubings
using a bath sonicator (Bransonics, Danbury, CT) and
were then pelleted using a microcentrifuge (1500 g, 5
min). DNA that was dissociated from the gold beads in
the TE buffer was quantified by measuring A260 using a
spectrophotometer. Mice were inoculated at two adja-
cent sites in the abdomen with vaccine DNA-coated gold
particles by propulsion using the PowderJet gene gun
according to the instructions of the manufacturer (Pow-
derJet). The animals were boosted at 4-week intervals
following primary inoculation, and a total of three or four
doses was administered as specified for each experi-
ment. Immunized animals were challenged at 14 days
after the last immunization with an oral dose of 100 ID50,
which was equivalent to 4 3 104 ffu of EDIM.
Determination of rotavirus antibody titers
Blood samples were collected using retroorbital cap-
illary plexus puncture before each immunization, before
challenge and at 21 days after challenge. Serum rotavi-
rus IgG and IgA, as well as stool rotavirus IgA were
determined as previously described (McNeal et al., 1994;
McNeal and Ward, 1995) with the following exception. To
determine post-vaccination titers in mice immunized with
plasmids containing VP4 or VP7 genes, the wells of
microtiter plates were coated with purified, triple-layered
EDIM particles (overnight, 4°C). After washing the plates,
serum specimens or mouse serum standards were
added and the analyses were continued as already
noted (McNeal et al., 1994). This change was necessary
to detect antibody to VP7 and VP4 proteins. The original
procedure was designed to detect primarily anti-VP6
responses. The same methods were used to measure
serum rotavirus IgG1 and IgG2a titers following DNA
vaccination except for two modifications: (1) the biotinyl-
ated goat anti-mouse IgG used to detect bound rotavirus
antibody was subtype specific (i.e., it specifically recog-
nized mouse IgG1 or IgG2a) and (2) the concentration of
rotavirus antibody was determined from a standard
curve that measured rotavirus antibody in nanograms
(ng) rather than units/ml. To generate this curve, EIA
plates were initially coated overnight with either goat
anti-mouse IgG or normal goat serum. After washing the
plates, serial twofold dilutions of purified mouse IgG1 or
IgG2a were added to the wells. The remaining steps
were identical to those used to measure rotavirus-spe-
cific IgG1 or IgG2a. NA to EDIM was measured by an
antigen reduction assay described previously (Knowlton
et al., 1991).
Western blot analyses
Western blot analyses were performed to determine
whether immune sera collected from mice immunized
with DNA vaccines could recognize cognate rotavirus
proteins. Triple-layered rotavirus particles were sub-
jected to SDS–PAGE and transblotted to nitrocellulose
sheets which were cut into strips. Strips of nitrocellulose
containing separated rotavirus proteins (3 mg per strip)
were incubated with mouse sera diluted at 1:100 in TBS
(50 mM Tris-HCl, pH 7.5; 100 mM NaCl; 0.1% Tween 20).
The sera that were tested included anti-EDIM rotavirus
serum obtained from two groups of orally immunized
mice. One group had low titers (GMT 5 24) of NA to
EDIM while the other group lacked EDIM NA (GMT ,
10). Immune sera from mice immunized with DNA vac-
cines were also tested. The nitrocellulose strips were
washed with TBS, probed with goat anti-mouse IgG con-
jugated to alkaline phosphatase (Life Technologies,
Gaithersburg, MD), washed with TBS, and then incu-
bated with 5-bromo-4-chloro-3-indolylphosphate (BCIP)
and nitroblue tetrazolium (NBT).
Detection of rotavirus shedding
Stool specimens were collected into 0.5 ml of Earle’s
balanced salt solution (EBSS) on the day of EDIM rota-
virus challenge and for 7 days following challenge. Sam-
ples were stored frozen (220°C), then homogenized and
centrifuged (1500 g, 5 min, 4°C) to remove debris before
being analyzed. Quantities of rotavirus in the fecal sam-
ples were determined by ELISA and expressed as A490
as previously described (McNeal et al., 1994).
Statistical methods
Statistical analyses of titers of rotavirus-specific anti-
bodies and amounts of shed rotavirus antigen between
groups of mice immunized with plasmids containing ro-
tavirus genes and control groups were performed by
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Student’s t test (unpaired, two-tailed). Differences be-
tween groups were considered significant when the
probability level (P) was #0.05.
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